Search

everythinglearnresearchcommunity

for

Search:↓

Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

RNA aptamers can specifically block FGF5-related cell growth, potentially treating related diseases or hair disorders.

Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.

Mice studies show that Protein Phosphatase 2A is crucial for cell growth, development, and disease prevention.

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

JAK inhibitors show promise for treating alopecia areata but have serious side effects.

Scientists found new, better-working inhibitors for a hormone-related enzyme.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Blocking LFA-1 prevents hair loss in mice.

JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.

Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.

Upadacitinib effectively treats psoriasis and lichen planus together.

Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.

Procyanidins from grape seeds reduce nerve pain by blocking specific proteins and inflammation.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.

Plumbagin may help protect cells, reduce inflammation, and has potential for treating various diseases, but more research is needed.

Monitoring TGF-β and linc-PINT expression may help identify and treat high-risk heart arrhythmia patients.

Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.

Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

ITK inhibitors may effectively treat alopecia areata.

Topical JAK inhibitors may help children with alopecia areata regrow hair.

Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.